Blood test may predict pancreatic cancer outcomes

NCT ID NCT05052671

Recruiting now Knowledge-focused Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at tiny pieces of tumor DNA (ctDNA) in the blood of 50 people with pancreatic cancer that can be surgically removed. Researchers want to see how often ctDNA is found and whether it relates to how long patients live without the cancer getting worse. The goal is to gather information that could lead to better ways to diagnose and treat this disease in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors use a simple blood test to better predict outcomes and personalize treatment for pancreatic cancer patients.
What could go wrong: This is a small, early-stage observational study. It is not testing a new treatment, so it may not directly change patient care. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREAS CANCER

Contacts and locations

Locations

Stephenson Cancer Center- Tulsa
NOT_YET_RECRUITING

Tulsa, Oklahoma, 74104, United States
University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.